Characteristics and prognosis of interval cancers after biennial screen-film or full-field digital screening mammography

2016 ◽  
Vol 158 (3) ◽  
pp. 471-483 ◽  
Author(s):  
Roy J. P. Weber ◽  
Rob M. G. van Bommel ◽  
Marieke W. Louwman ◽  
Joost Nederend ◽  
Adri C. Voogd ◽  
...  
2008 ◽  
Vol 49 (9) ◽  
pp. 975-981 ◽  
Author(s):  
S. Hofvind ◽  
B. Geller ◽  
P. Skaane

Background: Interval cancers are considered a shortcoming in screening mammography due to less favorable prognostic tumor characteristics compared to screening-detected cancers and consequently a lower chance of survival from the disease. Purpose: To describe the mammographic features and prognostic histopathological tumor characteristics of interval breast cancers. Material and Methods: A total of 231 interval breast cancer cases diagnosed in prevalently screened women aged 50–69 years old were examined. Thirty-five percent of the cases were retrospectively classified as missed cancers, 23% as minimal sign, and 42% as true negative (including occult cancers) in a definitive classification performed by six experienced breast radiologists. The retrospective classification described the mammographic features of the baseline screening mammograms in missed and minimal-sign interval cancers, while histopathological reports were used to describe the tumor characteristics in all the subgroups of interval cancers. Results: Fifty percent of the missed and minimal-sign interval cancers combined presented poorly defined mass or asymmetric density, and 26% calcifications with or without associated density or mass at baseline screening. Twenty-seven percent of invasive tumors were <15 mm for missed and 47% for true interval cancers ( P<0.001). Lymph node involvement was more common in missed (49%) compared with the true cases (33%, P<0.05). Conclusion: Missed interval cancers have less prognostically favorable histopathological tumor characteristics compared with true interval cancers. Improving the radiologist's perception and interpretation by establishing systematic collection of features and implementation of organized reviews may decrease the number of interval cancers in a screening program.


2015 ◽  
Vol 22 (2) ◽  
pp. 83-92
Author(s):  
Sune Bangsbøll Andersen ◽  
Sven Törnberg ◽  
Sini Kilpeläinen ◽  
Elsebeth Lynge ◽  
Sisse Helle Njor ◽  
...  

Breast Care ◽  
2019 ◽  
Vol 15 (5) ◽  
pp. 498-505
Author(s):  
Bettina Braun ◽  
Marc-André Kurosinski ◽  
Laura Khil ◽  
Joke Tio ◽  
Barbara Krause-Bergmann ◽  
...  

Introduction: Apart from saving lives, mammography screening programs (MSP) are expected to reduce negative side effects of treatment by detecting cancer earlier, when it is more responsive to less aggressive treatment. This study compared quality of life (QoL) among women with breast cancers that were detected either by screening mammography, as interval cancers, or clinically among women not participating in the MSP. Methods: Retrospective study of first-ever invasive breast cancers detected among MSP-eligible women aged 50–69 years between 2006 and 2012 in Münster, Germany. EORTC QLQ-C30 and -BR23 questionnaires were mailed to 1,399 cases still alive in 2015 (response rate 64.1%). Results: Women’s responses were obtained on average 6.1 years after diagnosis. Mean crude and age-adjusted scores for overall QoL, breast and body image (BBI), and five functional scales (FS) were comparable between groups of detection mode. Clearly lower adjusted means for most scores were observed in women with interval cancers, if time since diagnosis was less than 5 years. Cases younger than 60 years showed lower values for some FS, particularly among interval and screen-detected cases. Discussion/Conclusion: In summary, cases with breast cancer showed health-related score values that were similar to the general population of the same age. There was also no indication that mode of detection markedly influenced these scores. However, after adjusting for tumor stage and other influential factors, screening participants appeared more susceptible to score declines after a diagnosis of cancer than non-participants.


2016 ◽  
Vol 27 (2) ◽  
pp. 553-561
Author(s):  
Rob van Bommel ◽  
Adri C. Voogd ◽  
Marieke W. Louwman ◽  
Luc J. Strobbe ◽  
Dick Venderink ◽  
...  

BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Rob M. G. van Bommel ◽  
Roy Weber ◽  
Adri C. Voogd ◽  
Joost Nederend ◽  
Marieke W. J. Louwman ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document